#United States #San Francisco #Cytovale #IntelliSep #sepsis

Cytovale's Groundbreaking Study on IntelliSep Sepsis Test

In a dramatic advancement in sepsis detection and management, Cytovale® has released significant findings from a multicenter study that reveals substantial clinical and operational gains following the expansion of their IntelliSep sepsis test. This innovative diagnostic tool, cleared by the FDA, has been shown to dramatically improve patient outcomes across several hospitals.

Overview of Findings

Recently presented at the Society of Critical Care Medicine's 2026 Critical Care Congress, this study highlights impressive statistics indicating a reduction in sepsis mortality. The study’s data, which stemmed from an analysis of over 34,000 emergency department (ED) patients with suspected infections, suggests that implementing the IntelliSep test yielded a staggering 20%+ decrease in mortality rates and optimized resource utilization within the hospitals involved.

Key Outcomes Include:

• - A 19% relative reduction in sepsis mortality, achieved through the early identification of high-risk patients, leading to quicker life-saving interventions.
• - A 22% reduction in mortality among patients initially suspected of having sepsis but later determined to be non-septic, enabling timely diagnosis and appropriate treatment of underlying conditions.
• - An impressive 20% rise in ED discharges with no increase in the rate of patients returning within seven days.
• - A 30% fall in blood culture utilization, particularly among patients who were not ultimately diagnosed with sepsis, while still maintaining a high utilization rate among confirmed sepsis patients.

Successful Implementation Across Diverse Settings

The study marks the first-ever multicenter evaluation of the IntelliSep test’s impact across a variety of hospitals, from bustling emergency rooms to community facilities. Initially, the study began at the Our Lady of the Lake Regional Medical Center (OLORMC), and after witnessing tangible improvements in key clinical and operational metrics, it was expanded to four additional hospitals under the Franciscan Missionaries of Our Lady (FMOL) Health system. These included:
1. St. Elizabeth Hospital in Gonzales, LA (78 beds)
2. Our Lady of Lourdes Regional Medical Center in Lafayette, LA (340 beds)
3. St. Francis Medical Center in Monroe, LA (330 beds)
4. St. Dominic Hospital in Jackson, MS (570 beds)

According to Dr. Christopher Thomas, the Chief Quality Officer at FMOL Health, the entire team was enthusiastic about the results seen from the initial implementation. The consistent improvements across all participating hospitals suggested that IntelliSep could effectively be applied in numerous clinical environments, ultimately aiding clinicians with rapid and accurate assessments when evaluating patients for sepsis.

Dr. John Bruchhaus, Chief Medical Officer at St. Francis Medical Center, echoed these sentiments. He described how IntelliSep has enhanced early decision-making and positively impacted both ED patient throughput and blood culture efficiency, thereby reducing overall diagnostic costs while improving patient mortality and minimizing the length of hospital stays.

Future Implications

This groundbreaking study, titled 'Effect of Rapid Sepsis Test Adoption on Mortality, Discharge, Hospital-Free Days and Blood Cultures Across Four EDs in a Health System Early Experience,' will stir significant discussion and interest in critical care medicine. The potential for IntelliSep to facilitate early sepsis detection through machine learning and advanced testing capabilities can fundamentally transform how healthcare providers approach the management of sepsis, often referred to as a silent killer in emergency settings.

As Cytovale continues to refine their sepsis diagnostic offerings, this study reinforces their commitment to improving patient outcomes through innovative technology. With a focus on enhancing timely interventions, the IntelliSep test not only demonstrates significant improvements in response times but also highlights the need for proactive initiatives in emergency departments across the nation.

In summary, the positive trajectory that Cytovale's IntelliSep test offers signals hope for better sepsis care management and could lead to reduced fatalities in a condition that affects millions.

About Cytovale®

Cytovale is at the forefront of developing early detection technologies aimed at assessing immune activation, which help accelerate the time it takes from triage to necessary treatments. Based in San Francisco, the organization has attracted interest from major investors, including Norwest Venture Partners and Sands Capital. For additional insights on their solutions and advancements in sepsis diagnostics, visit cytovale.com.